After Taiwan FDA announced passing of the "RGSCTT", in order to help many critically ill patients prolonging for lives, it will open up to medical facilities to apply for cell therapy for patients in six categories, including autologous immune cells and autologous bone marrow mesenchymal stem cell transplantation. The open-up is not merely positive for critically ill patients, and also creates opportunities for cooperation between the technology owners and the medical facilities. Ever Supreme, a Taiwanese new drug research and development company, also announced that it has signed a memorandum of cooperation with more than 10 medical facilities such as China Medical University Hospital to provide immune cell therapy for treating malignant tumors, strokes, acute myocardial infarction, and others application. Ever Supreme has a complete layout plan in emerging cell medical market.
.jpg)